DexCom, Inc. reports news about its continuous glucose monitoring and glucose biosensing business for people with diabetes. Company updates commonly cover Dexcom G7 clinical evidence, product roadmap activity, U.S. and international revenue trends, margins, guidance, and presentations at diabetes technology and healthcare investor conferences.
Dexcom news also includes corporate governance developments, board appointments, management presentations, and long-term strategy discussions tied to its CGM portfolio, global commercialization, and innovation in metabolic health.
Dexcom (NASDAQ: DXCM) announced publication of its CONNECT randomized trial evaluating Dexcom G7 in adults with Type 2 diabetes not using insulin.
The study appeared in The New England Journal of Medicine. G7 users had an average 1.6% A1C reduction from a mean baseline of 8.8%, exceeding routine care's reduction by 0.9%. A1C measures longer-term blood sugar levels. Users spent approximately five additional hours daily in the 70–180 mg/dL glucose target range versus routine care. At 26 weeks, 68% of G7 users achieved A1C below 7.5%, and 46% achieved below 7.0%; 97% of participants were still using CGM, most daily. Among participants using GLP-1 therapies, continuous glucose monitoring produced an additional 0.9% A1C reduction versus routine care. Benefits were observed across demographic characteristics and glucose-lowering medications.
Dexcom (NASDAQ:DXCM) plans to release its third quarter 2026 financial results after market close on October 29, 2026.
Management will review the quarter’s performance on a conference call at 4:30 p.m. Eastern Time that day. A concurrent webcast will be available on the company’s investor relations website and archived for future reference.
Dexcom (DXCM) launched the fifth season of Dexcom U, its name, image and likeness program for college athletes with diabetes. The 2026–2027 roster includes 27 athletes across 13 sports, with 12 new and 15 returning participants, its largest roster to date. Dexcom plans to host Dexcom U Days this fall at selected athletes’ games, connecting young athletes with diabetes with collegiate participants.
A Dexcom survey found that young adults with Type 1 diabetes quitting sports after diagnosis fell from 24% in 2022 to 16% in 2026, while sports participation rose from 81% to 85%. Among respondents who quit sports, 62% feared low glucose levels and 54% found diabetes management during activity too complicated, up from 42%. The online survey included 1,004 U.S. adults with Type 1 diabetes or parents of children with the condition.
Dexcom (DXCM) released a global Type 2 diabetes survey report and announced a monitoring partnership with Team Novo Nordisk.
Based on surveys of more than 800 healthcare professionals and 2,500 people with Type 2 diabetes across eight countries, the report found that 89% of professionals believe continuous glucose monitoring (CGM) helps assess treatment adherence between visits. Among people with Type 2 diabetes, 55% reported limited CGM knowledge. Coverage and reimbursement barriers were cited by 90% of U.S. professionals and 53% in the other seven countries. Among current CGM users, 94% reported managing diabetes more independently, and 93% found CGM easy to use.
58% of Type 2 GLP-1 users pair CGM with their medication, while 27% of Type 2 non-insulin users do so. Dexcom will become the cycling team’s official CGM partner. The partnership is intended to support real-world research, education and awareness for people with Type 1 diabetes.
Dexcom (DXCM) has promoted Executive Vice President and Chief Financial Officer Jereme Sylvain to the additional role of Chief Operating Officer.
In this expanded position, Sylvain will oversee Dexcom’s global operations and quality teams to support the company’s growth vision and focus on operational excellence. He joined Dexcom in 2018 and has served as CFO since 2021, during which time he built a finance leadership team and helped guide growth and margin expansion. Dexcom’s CEO, Jake Leach, described Sylvain as an exceptional leader whose strategic judgment, operational discipline, and customer focus align with the company’s next phase of growth.
Dexcom (DXCM) has appointed Glenn Boehnlein to its Board of Directors, effective September 10, 2026. Boehnlein is a veteran healthcare and finance executive with over 20 years of medical technology experience, most recently serving as Vice President and Chief Financial Officer of Stryker Corporation. He brings expertise in financial leadership, capital allocation, strategic M&A, and operations to support Dexcom’s long-range growth plans in diabetes and metabolic health.
Dexcom (NASDAQ:DXCM) announced that management will present an update on the company at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, starting at approximately 8:00 AM EDT. The presentation will be webcast live, with access links and an archived replay available on the Dexcom Investor Relations website at investors.dexcom.com.
Dexcom (Nasdaq: DXCM) reported second quarter 2026 revenue of $1.308 billion, up 13% year-over-year (12% organic). U.S. revenue grew 11%, while international revenue increased 19% reported and 16% organic.
GAAP gross profit was $830.0 million (63.4% margin) and non-GAAP gross profit was $838.5 million (64.1% margin), both above prior-year levels. GAAP operating income reached $318.3 million (24.3% margin) and non-GAAP operating income was $328.3 million (25.1% margin), each improving 590 basis points versus Q2 2025. GAAP net income was $249.1 million, or $0.64 per diluted share, and non-GAAP net income was $269.1 million, or $0.70 per diluted share.
Dexcom raised its 2026 guidance to revenue of $5.18–$5.25 billion (11–13% growth), non-GAAP gross margin of ~64%, non-GAAP operating margin of ~23.5–24%, and adjusted EBITDA margin of ~31.5–32%. The company reported $1.95 billion in cash, cash equivalents and marketable securities and highlighted positive CONNECT trial results in type 2 diabetes not using insulin and the launch of its updated Stelo app experience.
Dexcom (NASDAQ: DXCM) has been selected by the U.S. Food and Drug Administration as the first participant in the FDA’s Technology-Enabled Meaningful Patient Outcomes (TEMPO) Digital Health Devices Pilot Program, an initiative to evaluate digital health technologies for chronic disease management using real-world evidence.
According to Dexcom, participation will enable an AI-powered glucose health program that integrates data from Dexcom G7 and Stelo with contextual information such as nutrition, activity, sleep and stress. The program is intended to support prediabetes and Type 2 diabetes screening, help improve glycemic control and HbA1c in people with prediabetes, and inform earlier intervention and broader cardiometabolic outcomes, while leveraging Dexcom’s clinician software platform for population-level care personalization.
Dexcom (NASDAQ: DXCM) announced that Health Canada has authorized the Dexcom G7 15 Day continuous glucose monitoring (CGM) system for adults 18+ with diabetes. According to Dexcom, G7 15 Day is the longest‑lasting and most accurate CGM system authorized by Health Canada, offering real-time glucose readings for up to 15.5 days per sensor and reporting an overall MARD of 8.0%.
The system is designed to lower sensor change frequency, simplify diabetes management and reduce waste, while retaining existing G7 features such as waterproof† sensors, direct-to-Apple Watch‡ connectivity, a 12‑hour sensor grace period, Dexcom Clarity app integration, data sharing with caregivers, and customizable alerts. While authorized, Dexcom G7 15 Day is not yet available for purchase in Canada; Dexcom plans education and support for patients and providers ahead of launch and invites Canadians to register online for availability updates.